Proteome Sciences and Moffitt Cancer Center collaborate on clinical mass spec assays for assessment of cancer patien

Proteome Sciences PLC, a global leader in applied proteomics and peptidomics, has entered into a collaboration agreement with the renowned Moffitt Cancer Center to develop mass spectrometry assays measuring certain key signaling and repair pathway proteins that can be adapted for tumor biopsy analysis in the clinic.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LONDON—Proteome Sciences PLC, a global leader in appliedproteomics and peptidomics, has entered into a collaboration agreement with therenowned Moffitt Cancer Center to develop mass spectrometry assays measuringcertain key signaling and repair pathway proteins that can be adapted for tumorbiopsy analysis in the clinic.
Continue reading below...
An illustration showing red cancer cells surrounded by white immune cells interacting on a dark textured background.
ExplainersWhy does immunotherapy work better for some cancers than others?
A powerful tool in modern oncology, immunotherapy doesn’t work the same for everyone. Researchers are exploring why and developing ways to improve its effectiveness.
Read More
According to Proteome Sciences, the technical collaborationwill enable the extension of Moffitt's activities to incorporate a large numberof key proteins and post-translational modifications to rapidly translatelaboratory tests into the direct management of cancer patients.
"We believe that knowledge of the molecular switchesoperating within each individual tumor will allow better selection andmonitoring of treatment efficacy," said Dr. John Koomen, principal investigatorat the cancer center, in a statement.
These new methods, capable of simultaneously measuring thesechanges across several pathways, are urgently needed to deliver better outcomesin all cancers, stated Dr. Ian Pike, chief operating officer of ProteomeSciences.
"We identified the expertise of the Koomen lab as beinghighly complementary to our own focus of profiling post-translationalmodifications in major human disease," he added. "We are delighted to beworking with John and look forward to launching a number of new MS assaysarising from this collaboration."
Located in Tampa, Fla., the Moffitt Cancer Center is aNational Institutes of Health Comprehensive Cancer Center. The center has 14affiliates in Florida, one in
Georgia, one in Pennsylvania and two in Puerto Rico.Additionally, Moffitt is a member of the National Comprehensive Cancer Network,a prestigious alliance of the country's leading cancer centers, and is listedin U.S. News & World Report as oneof "America's Best Hospitals" for cancer.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
A 3D rendering of red and yellow protein molecules floating in a fluid-like environment.
Discover approaches that shorten the path from DNA constructs to purified, functional proteins.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue